VANCOUVER, CANADA – September 6, 2016 – Evasc Neurovascular Enterprises ULC today announced today preliminary clinical results for the eCLIPs Bifurcation Remodeling System which demonstrates superior results over predicate treatment options.
Based on 17 deployments of eCLIPs in compliance with CE Mark indications for use, follow-up at 6-months showed no instance of a worsening in Raymond score between procedure and follow-up. Additionally, in no instance was a Raymond 3 observed at follow-up, suggesting improved efficacy over existing treatment options. In contrast, alternative devices have been shown to have worsening Raymond scores at follow-up in a significant number of cases, including Raymond 3, indicating aneurysm persistence or recurrence. A Raymond 1 score indicates complete aneurysm occlusion, a Raymond 2 score indicates occlusion except for a neck remnant, and a Raymond 3 score indicates the presence of an aneurysm.
“We are extremely encouraged by these early results, in which we’ve seen no cases of aneurysm recurrence after eCLIPs deployment,” said Dr. Donald Ricci, President and Chief Executive Officer of Evasc. “These preliminary efficacy results suggest an unprecedented long-term improvement to the patient outcome in treating bifurcation intracranial aneurysms.”
In development since 2008, eCLIPs is a patented endovascular device designed to treat 95% of cerebral aneurysm cases and is currently targeted for use in challenging wide-neck bifurcations. eCLIPs combines the best properties of stents and diverters and can be used for coil retention and to enhance flow disruption. eCLIPs avoids dangerous entry into the dynamic, fragile environment of the aneurysm sac while protecting and providing a platform for endothelial growth across the bifurcation neck. To date, eCLIPs has been used to treat cerebral aneurysms in over 30 patients in Canada and Europe.
Evasc Neurovascular is a privately held medical device company focused on the development of disruptive endovascular treatments for cerebral aneurysms. Evasc received CE mark approval in 2014. Evasc is headquartered in Vancouver, Canada.
Evasc Neurovascular is on the web at www.evasc.com.
For more information, contact Scott Wilson, +1-(604) 742-3811, email@example.com